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The inverse association between nicotine intake and Parkinson’s disease (PD) is well
established and suggests that this molecule could be neuroprotective through anti-
inflammatory action mediated by nicotinic receptors, including the α7-subtype (α7R).
The objective of this study was to evaluate the effects of an agonist of α7R, PHA 543613,
on striatal dopaminergic neurodegeneration and neuroinflammation in a rat model of PD
induced by 6-hydroxydopamine (6-OHDA) lesion. Adult male Wistar rats were lesioned
in the right striatum and assigned to either the PHA group (n=7) or the Sham group
(n=5). PHA 543613 hydrochloride at the concentration of 6mg/kg (PHA group) or vehicle
(Sham group) was intra-peritoneally injected 2 h before 6-OHDA lesioning and then at
days 2, 4, and 6 post-lesion. Positron emission tomography (PET) imaging was performed
at 7 days post-lesion using [18F]LBT-999 to quantify the striatal dopamine transporter
(DAT). After PET imaging, neuroinflammation was evaluated in same animals in vitro
through the measurement of the microglial activation marker 18 kDa translocator protein
(TSPO) by quantitative autoradiography with [3H]PK-11195. The DAT density reflecting
the integrity of dopaminergic neurons was significantly decreased while the intensity of
neuroinflammation measured by TSPO density was significantly increased in the lesioned
compared to intact striatum in both groups. However, these both modifications were
partially reversed in the PHA group compared to Sham. In addition, a significant positive
correlation between the degree of lesion and the intensity of neuroinflammation was
evidenced. These findings indicate that PHA 543613 exerts neuroprotective effects on the
striatal dopaminergic neurons associated with a reduction in microglial activation in this
model of PD. This reinforces the hypothesis that an α7R agonist could provide beneficial
effects for the treatment of PD.
Keywords: autoradiography, dopamine transporter, 6-hydroxydopamine, neuroinflammation, PET, TSPO
Abbreviations: α7R, α7 nicotinic receptor; CE, cerebellum; IST, intact striatum; LST, lesioned striatum; SUV, standard uptake
value; SUVr, standard uptake value ratio to CE.
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Introduction
Parkinson’s disease (PD) is the second most common age-related
neurodegenerative disorder after Alzheimer’s disease. It is char-
acterized by the relatively selective death of dopaminergic neu-
rons in the substantia nigra pars compacta leading to a stri-
atal dopamine deficit (1). PD is mainly sporadic and is usually
accompanied by motor symptoms, such as bradykinesia, rigidity,
postural instability, and resting tremor, although a rising occur-
rence of non-motor symptoms is now recognized (2). Currently,
the treatment of PD is only symptomatic and no efficient neu-
roprotective or disease modifying approaches are available. The
search for such curative treatments requires to explore various
molecular pathways involved in order to focus on drugs able to
block or curb disease progression. One neuropathological feature
of PD is the occurrence of neuroinflammatory processes, which
manifests in part through the activation of microglial cell and
astrocytes in the substantia nigra (3–5). Regulating neuroinflam-
mation appears therefore to be a potential therapeutic approach;
however, despite promising results obtained with different anti-
inflammatory drugs in animal models (6, 7), clinical studies have
been disappointing (8).
As previously described in the peripheral nervous system (9),
it has been shown that downregulation of the microglial acti-
vation can be induced through the activation of α7 nicotinic
receptors (α7Rs) harbored by microglial cells (10). α7Rs are the
acetylcholine nicotinic receptors most represented, with the α4β2
subtype, in mammalian brain and have several pharmacologi-
cal characteristics, such as a high permeability to calcium, low
sensitivity to acetylcholine, and high affinity for α-bungarotoxin
(11). They are localized both on neurons (12) and glial cells (13).
Besides their effects on neurotransmission, α7Rs are involved in
the modulation of neuroinflammatory processes, and agonists of
these receptors are more efficient than acetylcholine at inhibiting
the inflammatory signaling and production of pro-inflammatory
cytokines from immune cells (14). In addition, several studies
conducted in animal models support the idea that drugs act-
ing at nicotinic acetylcholine receptors may be beneficial for
PD (15). In particular, it has recently been suggested that the
beneficial effect on the dopaminergic function observed with
the α7R agonist ABT-107 could be linked to a reduction of the
glutamate excitotoxicity leading to the promotion of neuronal
integrity (16).
In this study, we used a selective agonist of α7R, PHA 543613
(17, 18), in a rat model of PD induced by unilateral striatal
administration of 6-hydroxydopamine (6-OHDA) to investigate
whether this compound has a protective effect on dopamin-
ergic neurons through an anti-inflammatory mechanism. For
this aim, we measured the striatal dopamine transporter (DAT)
by in vivo positron emission tomography (PET) imaging using
the fluorinated derivative of PE2I, (E)-N-(4-fluorobut-2-enyl)2β-
carbomethoxy-3β-(4’-tolyl)nortropane or LBT-999 that we previ-
ously developed (19, 20). The neuroinflammation was evaluated
through the density of the 18 kDa translocator protein (TSPO)
using a quantitative autoradiographic method with the reference
ligand of TSPO [3H]PK-11195, which has been widely used in
rodent and human brains (21–24).
Materials and Methods
Animals
All procedures were conducted in accordance with the Euro-
pean Community Council Directive 2010/63/EU for laboratory
animal care and the experimental protocol was validated by the
Regional Ethical Committee (Authorization N°00434.02). Exper-
iments were carried out on adult male Wistar rats (CERJ, France)
weighing 290–300 g at the beginning of experiments. Animals
were housed in groups of two per cage in a temperature (21 1°C)
and humidity (55 5%) controlled environment under a 12-h
light/dark cycle, with food and water available ad libitum.
6-OHDA Lesion
The experimental design was performed according to a previ-
ously described procedure (25). Twenty minutes before surgery,
rats were injected intra-peritoneally with pargyline (50mg/kg,
Sigma, Saint-Quentin Fallavier, France). Rats were anesthetized
with isoflurane (4%, 500mL/min) and placed on a stereotaxic
apparatus (Stoelting, Phymep, Paris, France) and maintained
under isoflurane 2.5% (500mL/min) during surgery. The skull
was exposed and small holes were made with a dental drill. Lesion
was carried out by unilateral intrastriatal injection of 6-OHDA
hydrochloride (1mg/mL, Tocris Bioscience, Bristol, UK). A total
of 10μg of 6-OHDA was administered in two areas of the right
striatum (1mg/mL in 0.01% ascorbic acid, pH 4.5, i.e., 5μg in 5μL
for each area) with a Hamilton syringe (gage 25, Hamilton, Massy,
France) at a flow rate of 1μL/min. Coordinates from bregma were
AP=+0.5mm, L= 2.5mm, P= 5mm, and AP= 0.5mm,
L= 4mm, P= 5mm according to Paxinos and Watson atlas
(26). The needle was left in place for 4min after injection and
then removed slowly to optimize toxin diffusion. After surgery,
the rats were given buprenorphine (0.05mg/kg sub-cutaneously)
for postoperative pain and were allowed to recover from surgery
for 7 days before being subjected to the imaging experiments.
Treatment with the α7 Receptor Agonist PHA
543613
PHA 543613 hydrochloride (Tocris Bioscience, Bristol, UK; 17,
18) was dissolved in sterile water and intra-peritoneally injected
at the concentration of 6mg/kg (300μL/300 g body weight) 2 h
before 6-OHDA lesioning and then at days 2, 4, and 6 post-lesion
(cumulative dose of 24mg/kg). Twelve rats were included in this
study and separated into two groups as follows: seven lesioned
rats received the treatment (PHA group) and five lesioned rats
received intra-peritoneally injection of vehicle at the same time
points (Sham group).
Preparation of the Tracer
No-carrier-added [18F]LBT-999 was prepared as previously
described (27). The tracer was produced via direct nucleophilic
substitution from its chloro analog by adding 3mg of the precur-
sor in 1mL of DMSO to the dry [18F] KF/K2.2.2 complex. After
heating at 165°C for 10min, the mixture was cooled and puri-
fied by HPLC (Alltima, C18, 250 10mm, 5μm column) using
ammonium acetate 0.1M/acetonitrile 4/6 as the mobile phase at
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a 4mL/min flow rate. In these conditions, time retention was
13.5min. The desired fraction was collected, diluted in water, and
the [18F]LBT-999 was trapped on a t-C18 light SepPak cartridge.
The cartridge was rinsed with 5mL of injectable water, and the
[18F]LBT-999 was eluted with 0.5mL of ethanol. Formulation
was completed by the addition of 3.5mL of NaCl 0.9%. Quality
control was performed by HPLC (Alltima, C18, 250 4.6mm,
5μm column) using ammonium acetate 0.1M/Acetonitrile 3/7.
[18F]LBT-999 was obtained with a radiochemical purity >98%
and with a mean specific activity of 65 10GBq/μmol.
PET Imaging and Data Analyses
Positron emission tomography imaging was performed at 7 days
post-lesion. Acquisitions were made on a microPET eXplore
VISTA-CT system (GE Healthcare, France) which has an effec-
tive axial/trans axial field of view (FOV) of 4.8/6.7 cm, a spatial
resolution less than 2mm and a sensitivity above 2.5% in the
whole FOV. Animals were anesthetized with isoflurane (Baxter,
France), at 4–5% in O2 for induction and then 1.5–2% during
scanning. For imaging, each rat was placed on a thermo-regulated
bed (Minerve, France) in the prone position with a nose cone. The
brain was positioned on the center of the FOV. Before PET acqui-
sition, a 5-min computed tomography (CT) scan was acquired for
attenuation correction. A bolus injection of 37MBq/300 g body
weight of [18F]LBT-999 in saline was administered into the tail
vein. During PET acquisition, the respiratory rate and body tem-
perature were monitored and kept as constant as possible. Each
acquisition lasted 50min and PET list-mode scans were rebinned
into 27 frames: 4 10-s frames followed by 4 20-s frames, 4 60-s
frames, 14 180-s frames, and 1 120-s frame. Each PET scan was
corrected for random, scatter, and attenuation, and the images
were reconstructed using a 2-DOSEM algorithm (GEHealthcare,
France) into voxels of 0.3875mm 0.3875mm 0.775mm. All
images were analyzed using PMOD (3.403, PMOD Technolo-
gies, Zurich, Switzerland, www.pmod.com). The PET-corrected
images were used for standard uptake value (SUV) calculations.
For each PET scan, data were summed over the first 5min after
radiotracer injection to create a pseudo perfusion image. This
image reflects the initial flow-dependent activity and was reg-
istered with the CT image through a known hardware registra-
tion (PET to CT transformation). CT scans were also recorded
using a rat brain magnetic resonance imaging template (MRI-
Template) (PMOD) (28) and a rat brain MRI-Template to CT
transformation was saved. All PET images, after checking for
potential head movements, were co-registered in a single interpo-
lation to the Schiffer rat brain MRI-Template by a combination
of these two transformations (MRI-Template to CT, and PET
to CT transformations). The inverse combined transformation
was calculated. The Schiffer MRI-template was processed in the
PET space images using the inverse transformation applied on
the originals dynamic PET data and statistics for the regions of
interest (ROIs) were extracted. PET images were analyzedwith the
ROIs for the left striatum (i.e., intact striatum, IST), right striatum
(i.e., lesioned striatum, LST), and cerebellum (CE). In this study,
the standard uptake value ratio (SUVr) was used as quantitative
criterions. All SUVrs were calculated using the CE as the reference
region.
Autoradiographic Study
After the PET scan, rats were humanely killed by decapitation
under light isoflurane anesthesia, and their brains were carefully
removed on ice for autoradiographic experiments according to
Ref. (25). Brains were frozen in isopentane cooled at  35°C and
stored at  80°C. Coronal brain sections 20-μm thick were cut
with a cryostat (CM 3050S, Leica, Germany) at  20°C, collected
on gelatinized slides and stored at  80°C for at least 4 days. A
total of six sections per brain were studied for each animal. The
density of TSPO binding sites was measured by in vitro autora-
diographic experiments using [3H]PK-11195 (specific activity
3.06GBq/μmol; Perkin Elmer, Norwalk, CT, USA) at 1 nmol/L
in a 50-mmol/L Tris–HCl buffer pH 7.4. Brain sections were
allowed to equilibrate at room temperature (RT) for 3 h, then were
incubated with 1 nmol/L [3H]PK-11195 in 50mmol/L Tris–HCl
buffer pH 7.4 at RT for 60min. Non-specific binding was assessed
in the presence of 1μmol/L PK-11195 (Sigma Aldrich, France).
Sections were rinsed twice in ice cold buffer (4°C) for 5min, then
briefly in distilled water at 4°C and dried at RT. Dry sections were
made conductive by an application of metal electric tape (3M,
Euromedex) on the free side and then placed in the gas chamber
of the β-imager™ 2000 (Biospace Lab, Paris, France). Acquisitions
were collected for 4 h. Two anatomical ROIs, i.e., the LST and
IST were selected manually and identified in Paxinos and Wat-
son atlas (26). Using the β-vision software (Biospace Lab, Paris,
France), the level of bound radioactivity was directly determined
by counting the number of β-particles emitted from the delineated
area. The radioligand signal in the ROIs was measured for each
rat and expressed as counts per minute per square millimeter
(cpm/mm2). Specific bindingwas determined by subtracting non-
specific binding from total binding. Radioactivity was quanti-
fied using an image analyzer (M3-vision Biospace Instruments,
France). The percentage increase of TSPO binding in LST vs. IST
was calculated as:
[LST  IST]
IST  100
Statistical Analysis
For PET imaging and autoradiographic studies, results were
expressed as meanmean standard error (SEM). Comparisons
between the binding in the LST and IST were performed using
the Wilcoxon test one-tailed. To compare the two groups of rats
(PHA vs. Sham), a Mann–Whitney test was used. The level of
significance was p 0.05. Correlation between PET imaging and
autoradiography was estimated by using a one-tailed Spearman
test (GraphPad Instat, GraphPad Software, San Diego, CA, USA).
The level of significance was p 0.05. Statistical analyses were
performed using the GraphPad Prism software version 5.
Results
Animals
No physiological issues and no difference in body weight were
observed between animals in the PHA and Sham groups (weight
on the day of lesion: 300 4 vs. 297 6 g, respectively; weight at
day 7 post-lesion: 313 5 vs. 301 6 g, respectively).
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PET Imaging
Positron emission tomography images are presented in Figure 1.
After [18F]LBT-999 injection, a progressive accumulation of
radioactivity was observed mainly in the IST (Figure 1A). Static
PET images revealed that accumulation of [18F]LBT-999 on the
lesioned striatum was greater in PHA rats than in Sham rats
(Figures 1B,C).
The time activity curves (Figure 2A) showed a rapid uptake of
[18F]LBT-999 in the ROIs (i.e., the IST, LST, and CE) after intra-
venous bolus injection. In the CE, the uptake decreased rapidly
and remained low and stable after 20min post-injection in both
groups (SUV in the PHAgroup: 0.97 0.06, and 0.99 0.08 in the
Sham group). The uptake remained high and stable in the IST in
both groups (SUV in the PHA group: 3.99 0.33, and 3.84 0.31
in the Sham group). By contrast, the values observed in the LST
were reduced in comparison to those in the IST in both groups
(SUV in the PHA group: 1.41 0.19, and 0.98 0.11 in the Sham
group).
The analysis of SUVrs to CE (Figure 2B) showed a significant
reduction in the LST compared to the IST, both in the PHA
(1.58 0.23 vs. 4.34 0.42, p< 0.05 Wilcoxon test) and Sham
(0.99 0.07 vs. 3.94 0.37, p< 0.05Wilcoxon test) groups. These
SUVrs were similar in the IST in both groups (PHA: 4.34 0.42
and Sham: 3.94 0.37), whereas in the LST the SUVr was slightly
higher in the PHA than in the Sham group (1.58 0.23 and
0.99 0.07, respectively). In addition, the percentage of decrease
in the SUVr (which reflects the intensity of the lesion) was
significantly lower in the PHA group compared to the Sham
group (64.6 2.9 vs. 73.7 3.7%, p< 0.05, Mann–Whitney test)
(Figure 2C).
Autoradiographic Study
The TSPO density was evaluated on adjacent brain sections
by [3H]PK-11195 binding in the IST and LST from each rat
in both groups as illustrated in Figure 3A. The specific bind-
ing of [3H]PK-11195 (Figure 3B) in the IST was low and
similar between the PHA and Sham groups (1.53 0.18 and
1.40 0.29 cpm/mm2, respectively). In the LST of both groups,
this binding was significantly increased (PHA group: 3.69 0.32
vs. 1.53 0.18 cpm/mm2 in the IST p< 0.05 Wilcoxon test; Sham
group: 4.85 0.29 vs. 1.40 0.06 cpm/mm2 in the IST, p< 0.05
Wilcoxon test). However, this increase was significantly lower in
the PHA group than in the Sham group (24% lower, p< 0.05,
Mann–Whitney test). In addition, as shown in Figure 3C, the
percent of increase of TSPO binding in LST vs. IST was signif-
icantly lower in the PHA group compared to the Sham group
(157.5 30.9 vs. 262.2 20.6%, p< 0.05, Mann–Whitney test).
Correlation Between PET Imaging and
Autoradiography
The correlation between PET imaging results (expressed as the
degree of lesion, i.e., % tracer binding in LST vs. IST) and
FIGURE 1 | PET brain images with [18F]LBT-999. (A) Coronal PET images in a 6-OHDA lesioned rat with [18F]LBT-999 from 1.8 to 50min after bolus injection of
the tracer. PET brain static sagittal and coronal images with [18F]LBT-999 co-registered with the MRI-Template in a Sham rat (B) and in a PHA rat (C).
FIGURE 2 | Quantitative results from PET brain images with
[18F]LBT-999. (A) Mean-time activity curves of [18F]LBT-999 SUVs in the IST,
LST, and CE, in Sham (blue) and PHA (red) rats. (B) Mean-time activity curves of
SUVr to CE of tracer accumulation in IST and LST in Sham (blue) and PHA (red)
rats. (C) Percentage of lesion in Sham (blue) and PHA (red) rats. *p<0.05
compared with Sham (Mann–Whitney test). Abbreviations: CE: cerebellum, IST:
intact striatum, LST: lesioned striatum, SUV: standard uptake value, SUVr:
standard uptake value ratio to CE.
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FIGURE 3 | Autoradiographic analysis of TSPO density with
[3H]PK-11195. (A) Representative total (left side) and non-specific (right
side) binding of [3H]PK-11195 obtained on 20μm-thick coronal brain
sections in Sham rats (upper panel) and in PHA rats (lower panel). Note that
the cortical signal reflects the binding resulting from the mechanical lesion
induced by the needle. (B) Quantitative autoradiographic measurements of
TSPO density expressed as specific binding of [3H]PK-11195 in IST and
LST from Sham (blue) and PHA (red) rats (mean cpm/mm2SEM).
(C) Percentage of TSPO binding in LST vs. IST (meanSEM%) from Sham
(blue) and PHA (red) rats.*p<0.05 (Mann–Whitney test). #p<0.05
(Wilcoxon test). Abbreviations: TSPO, translocator protein; IST, intact
striatum; LST, lesioned striatum.
FIGURE 4 | Correlation between PET imaging and autoradiography.
The correlation is reported for both groups. Sham rats are represented in blue
and PHA rats are in red. A one-tailed Spearman test was used (p= 0.05,
rho= 0.49).
autoradiography (expressed as a percent of neuroinflammation,
i.e., % TSPO binding in LST vs. IST) is shown in Figure 4.
The degree of lesion measured by PET imaging was positively
correlated with the intensity of neuroinflammation (p= 0.05,
rho= 0.49).
Discussion
To date, no treatment has been recognized as useful neuroprotec-
tive approach for PD. Neuroinflammation is believed to be a key
pathophysiological mechanism that could be targeted to achieve
neuroprotection (29). A number of epidemiological and experi-
mental evidence have converged to demonstrate a neuroprotective
effect of nicotine in PD (30), involving particularly theα7-subtype
of nicotinic receptors (31). Interestingly, this effect could be at
least partly mediated by the modulation of neuroinflammation
affected by these receptors (11). On this basis, we evaluated in
this study the effects of a potent agonist of α7R, PHA 543613, on
the neurodegeneration of dopaminergic neurons and associated
microglial activation in a rat model of PD.
To date, little is known on the potential effects of α7R agonists
in PD. As we aimed to induce a potential neuroprotective effect,
we used a partial lesion model which corresponds to an early
symptomatic stage of PD (32, 33).
Because the striatal DAT has proven to be a marker that
correlates with the level of dopaminergic denervation (30, 34), we
studied the integrity of striatal dopaminergic nerve endings using
PET imaging with the fluorinated derivative of PE2I, (E)-N-
(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4’-tolyl)nortropane
or LBT-999 that we previously developed (19, 20). We recently
demonstrated the ability of [18F]LBT-999 to quantify in vivo the
DAT in the rat brain with high reproducibility, sensitivity, and
specificity (27). In addition, this tracer has proven useful in a rat
model of PD to quantify the lesions and as a treatment for cell
restoration (35).
In order to evaluate the effects of PHA on neuroinflammation,
we measured the density of the 18 kDa TSPO in the brain of PD
rats after exploration by PET imaging. Indeed, the inflammatory
reaction in the brain involves the activation of microglia (36)
leading to a dramatic increase in the expression of the TSPOwhich
can thus be considered as a sensitive biomarker of this activation
(37, 38).We used a quantitative autoradiographicmethodwith the
reference ligand of TSPO [3H]PK-11195, which has been widely
used in rodent and human brains (21–24).
Our PET experiment showed that at 7 days after 6-OHDA
lesion, the specific accumulation of [18F]LBT-999 in the striatum,
measured as the SUVr toCE as reference region, was high and sim-
ilar on the intact side of all animals, and reduced on the lesioned
side, as expected. However, we observed that the degree of lesion
of dopaminergic neurons on the lesioned side, calculated as the
percentage of tracer binding in the lesioned vs. intact striatum
was slightly but significantly reduced in the PHA-treated group
compared to Sham group (64 vs. 74% lesion, respectively). These
results are in agreement with a partial neuroprotective effect of
the α7R agonist on dopaminergic nerve endings. It is known that
PHA 543613 is a potent and selective α7R agonist (17, 18), which
has been shown to reduce induced brain edema in a mouse model
through the inhibition ofGSK-3β (39, 40). Similarly, PHA568487,
an α7R agonist closely related to PHA 543613, has been shown to
reduce the severity of an ischemic stroke (41).
In rodent models of PD, neuroprotective effects have already
been described with different α7R agonists, i.e., DMXBA (42),
PNU-282987 (43) and more recently ABT-107 (16). In several of
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these studies microglial activation was reduced by treatment with
α7R agonists, but the effects on neuroinflammatory parameters
were observed at much earlier time’s post-lesion than the effects
on dopaminergic parameters (42, 43). We demonstrated herein
a strong relationship between the effects of the α7R agonist
on the dopaminergic neurons integrity and on neuroinflamma-
tion, because α7R agonist treatment reduced both dopaminergic
neuron loss and microglial activation in the same animal. This
is reinforced by the fact that we showed a significant positive
correlation between the decrease of [18F]LBT-999 accumulation
and [3H]PK-11195 binding, which confirms that the upregula-
tion of TSPO is directly correlated with the degree of neuronal
damage (38).
Taking into account the small number of animals studied,
our present findings can be considered as preliminary. In addi-
tion, several complementary experiments such as the evaluation
of dopaminergic neuron integrity through TH immunostaining,
behavioral tests assessing the dopaminergic function, and differ-
ent experimental designs with various doses and administration
points would be performed to confirm our findings. Nevertheless,
we showed that in vivo PET exploration in rodent models can be
useful to evaluate different neuroprotective approaches using a
variety of pharmacological compounds and experimental designs.
In this field, the use of the TSPO PET tracer [18F]DPA-714 in
parallel to PET tracers of neurodegeneration would be of great
value in rodent models of neurodegenerative disease, as recently
done (44).
Our findings indicate that PHA 543613, a high affinity and
selective α7R agonist, partially preserved the integrity of striatal
dopaminergic nerve endings and reduced neuroinflammation in
6-OHDA-lesioned rats. This reinforces the hypothesis that α7R
agonists may be beneficial in PD.
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